Expression of cyclooxygenase (COX)-2 in head and neck cancer and inhibitory effect of COX-2 inhibitors on tumor growth

环氧合酶(COX)-2在头颈癌中的表达及COX-2抑制剂对肿瘤生长的抑制作用

基本信息

  • 批准号:
    12470453
  • 负责人:
  • 金额:
    $ 6.78万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2000
  • 资助国家:
    日本
  • 起止时间:
    2000 至 2002
  • 项目状态:
    已结题

项目摘要

This study was designed to examine the immunohistochemical expression of cyclooxygenase (COX)-2 in head and neck cancer, and the inhibitory effect of COX-2 inhibitors on head and neck cancer cell growth. Based on the above experimental data, the chemopreventive potential of COX-2 inhibitors against DMBA-induced hamster cheek pouch carcinogenesis as animal model and synergistic effect of COX-2 inhibitors with anticancer agents as therapeutic strategy are also investigated. The results obtained were as follows.1) The immunohistchemical examination showed the expression of COX-2 protein n both squamous cell carcinoma (SCC) of the head and neck and salivary gland carcinoma (SGC). The expression rate was higher in SGC than SCC. In SCC, COX-2 expression became higher as the degree of tumor differentiation was lower, and undifferentiated carcinomas all showed high expression. In addition, metastatic lesions demonstrated significantly higher expression than primary lesions.2) The COX-2 express … More ion was shown not only in SCC but also in epithelial hyperplasia, epithelial dysplasia and carcinoma in situ. The extent of the expression was increased toward carcinogenesis. There was a close correlation between COX-2 expression and topoisomerase II α expression, and a tendency of poor prognosis in SCC patients with high expression of these enzymes.3) The COX-2 inhibitors inhibited the growth of head and neck cancer cell lines in a dose-dependent manner via apoptosis induction. These effects were more prominent in celecoxib than sulindac and etodolac. Celecoxib inhibited PGE_2 production and COX-2 expression efficiently.4) The non-cytotoxic or less cytotoxic concentrations of celecoxib augmented the growth inhibitory effect of anticancer agents such as adriamycin, vincristine and bleomycin by 2 to 10-fold via increased apoptosis induction.5) Oral administration of celecoxib retarded the onset of carcinoma formation, tumor growth and death in DMBA-induced hamster cheek pouch carcinogenesis model, although all hamsters developed SCC by DMBA application. Less
本研究通过免疫组织化学方法检测环氧合酶(考克斯)-2在头颈部肿瘤中的表达,并观察考克斯-2抑制剂对头颈部肿瘤细胞生长的抑制作用。基于上述实验数据,还研究了考克斯-2抑制剂对DMBA诱导的仓鼠颊囊癌变的化学预防潜力作为动物模型,以及考克斯-2抑制剂与抗癌药物的协同作用作为治疗策略。结果表明:1)免疫组化显示考克斯-2蛋白在头颈部鳞癌和涎腺癌中均有表达。胃癌中的表达率高于鳞癌。在鳞癌中,考克斯-2表达随肿瘤分化程度的降低而增高,未分化癌均呈高表达。此外,转移灶的表达明显高于原发灶。2)考克斯-2表达 ...更多信息 不仅在鳞状细胞癌中,而且在上皮增生、上皮不典型增生和原位癌中均有表达。表达的程度随着癌变的进展而增加。考克斯-2和拓扑异构酶II α的表达密切相关,高表达者预后差; 3)考克斯-2抑制剂通过诱导细胞凋亡抑制头颈癌细胞株的生长,呈剂量依赖性。塞来昔布的这些作用比舒林酸和依托度酸更显著。塞来昔布可有效抑制PGE_2的产生和考克斯-2的表达。4)塞来昔布的非细胞毒性或较小的细胞毒性浓度通过增加细胞凋亡诱导作用使抗癌药物如阿霉素、长春新碱和博来霉素的生长抑制作用增强2至10倍。5)塞来昔布口服给药可延缓肿瘤形成。在DMBA诱导的仓鼠颊囊癌发生模型中的肿瘤生长和死亡,尽管所有仓鼠通过DMBA应用发展了SCC。少

项目成果

期刊论文数量(16)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sakurai K., Urade M., Noguchi K., Kishimoto H., Ishibashi M., Yasoshima H., Yamamoto T., Kubota A.: "Increased expression of cyclooxygenase-2 in human salivary gland tumors"Pathology International. 51. 762-769 (2001)
Sakurai K.、Urade M.、Noguchi K.、Kishimoto H.、Ishibashi M.、Yasoshima H.、Yamamoto T.、Kubota A.:“人类唾液腺肿瘤中环氧合酶 2 的表达增加”国际病理学。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hashitani S., Urade M., Nishimura N., Maeda T., Takaoka K., Noguchi K., Sakurai K.: "Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines"
Hashitani S.、Urade M.、Nishimura N.、Maeda T.、Takaoka K.、Noguchi K.、Sakurai K.:“塞来昔布(一种选择性环氧合酶 2 抑制剂)在人体中诱导细胞凋亡并增强抗癌药物的细胞毒性
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hashitani S., Urade M., Nishimura N., Maeda T., Takaoka K., Noguchi K. and Sakurai K.: "Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lin
Hashitani S.、Urade M.、Nishimura N.、Maeda T.、Takaoka K.、Noguchi K. 和 Sakurai K.:“塞来昔布(一种选择性环氧合酶 2 抑制剂)在人体中诱导细胞凋亡并增强抗癌药物的细胞毒性
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
櫻井一成, 黒田純子, 橋谷 進, 西村則彦, 野口一馬, 岸本裕充, 浦出雅裕: "口腔扁平上皮癌の原発、転移巣におけるCyclooxygenase(COX)-2蛋白発現の比較検討"日本口腔科学会雑誌. 51巻6号. 366-373 (2002)
Kazunari Sakurai、Junko Kuroda、Susumu Hashitani、Norihiko Nishimura、Kazuma Noguchi、Hiromitsu Kishimoto、Masahiro Urade:“口腔鳞状细胞癌原发性和转移性病变中环氧合酶 (COX)-2 蛋白表达的比较研究”日本口腔医学会杂志。第 51 卷,第 6 期。366-373 (2002)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
櫻井一成, 黒田純子, 橋谷進, 西村則彦, 野口一馬, 岸本裕充, 浦出雅裕: "口腔扁平上皮癌の原発,転移巣におけるCyclooxygenase(COX)-2蛍日発現の比較検討"日本口腔科学会雑誌. 51巻6号. 366-373 (2002)
Kazunari Sakurai、Junko Kuroda、Susumu Hashitani、Norihiko Nishimura、Kazuma Noguchi、Hiromitsu Kishimoto、Masahiro Urade:“口腔鳞状细胞癌原发性和转移性病变中环氧合酶 (COX)-2 表达的比较研究”日本口腔学会科学杂志学会。第 51 卷,第 6 期。366-373 (2002)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

URADE Masahiro其他文献

URADE Masahiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('URADE Masahiro', 18)}}的其他基金

Isolation and identification of oral cancer stem cells and development of specific therapy for cancer stem cells
口腔癌干细胞的分离鉴定及癌症干细胞特异性治疗的开发
  • 批准号:
    21390544
  • 财政年份:
    2009
  • 资助金额:
    $ 6.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Analysis of mechanisms of oral cancer metastasis via chemokine signals and molecular target therapy for inhibition of metastasis
趋化因子信号分析口腔癌转移机制及抑制转移的分子靶向治疗
  • 批准号:
    18390549
  • 财政年份:
    2006
  • 资助金额:
    $ 6.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Study on the inhibition of chemical carcinogenesis of buccal mucosa with a macrophage activating factor
巨噬细胞激活因子抑制颊黏膜化学癌变的研究
  • 批准号:
    09672086
  • 财政年份:
    1997
  • 资助金额:
    $ 6.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study on the antitumor arug resistance in oral squamous carcinoma cells-Analysis of resistance mechanism and development of therapy for overcoming o the resistance-
口腔鳞癌细胞抗肿瘤药物耐药性研究-耐药机制分析及克服耐药的治疗方法开发-
  • 批准号:
    07457502
  • 财政年份:
    1995
  • 资助金额:
    $ 6.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Significance of dipeptidyl peptidases as marker enzyme of oral cancer
二肽基肽酶作为口腔癌标志酶的意义
  • 批准号:
    03670944
  • 财政年份:
    1991
  • 资助金额:
    $ 6.78万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Molecular mechanisms of cyclooxygenase(COX)-2-induction in human polymorphonucleocytes
人多形核细胞环氧合酶(COX)-2诱导的分子机制
  • 批准号:
    11670767
  • 财政年份:
    1999
  • 资助金额:
    $ 6.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了